CAR-T Market Report, 235 Pages
Recently Released—August 2021
For the next 48 hours, you can claim this report for an incredible 20% off. Act fast, because this offer expires soon and you won’t want to miss it.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.
Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, an exponential increase in clinical trial activity, proliferative M&A activity, and lucrative IPOs have created a robust CAR-T cell market. This billion dollar market would not have been possible without the remarkable efficacy of Kymriah, Yescarta, Tecartus, Breyanzi, and Abecma in treating several types of blood cancers.
CAR-T Cell Therapy Market
In 2012, there were only 12 clinical trials investing CAR-T cell therapy products. Today, that number has risen to 514. Between 2017 and 2021, four CAR-T products reached the market, and this number is projected to reach double digits by 2024.
The earliest approvals, Kymriah and Yescarta, have been commercially available since 2017 and 2018, respectively. They’ve been infused into nearly a half million patients worldwide. In July 2020, the U.S. FDA approved a third CAR-T cell therapy, Kite Pharma’s brexucabtagene autoleucel (sold as Tecartus). In February 2021, Breyanzi became the fourth CAR-T approval and the first product with RMAT designation to be licensed by the FDA. In March 2021, the U.S. FDA approved Abecma for the treatment of relapsed or refractory multiple myeloma after four or more prior lines of therapy.
All of the approved CAR-T products and nearly 75% of the ongoing clinical trials take an autologous treatment approach. Autologous (self-derived) CAR-T cells are expensive to produce because they are manufactured on a patient-by-patient basis. At times, autologous production can be hampered by a shortage of CAR-T cells or viral vectors. The cost of autologous CAR-T therapy is further escalated by the need for a complex cold chain during transportation. Another key issue is the “vein-to-vein” time or the time that elapses between apheresis and product delivery.
Thus, CAR-T therapies are most often recommended for the end-stage patients who have exhausted all the other treatment options. These challenges drive up the price, making CAR-T therapy unaffordable for a large percentage of patients.
To support the adoption of CAR-T cell therapies, the industry is taking measures to mitigate these challenges. Several CAR-T players have started using efficient gene-transfer tools to impregnate the T cells with CARs. There are numerous examples of partnerships to develop CRISPR and electroporation technologies to modify the T cells. Some companies are also using “on-off” switches that can turn off CAR-T cells to prevent toxicity.
Unfortunately, the goal of achieving CAR-T success against solid tumors remains elusive thus far, with clinical trials demonstrating a severely limited response.
Trends in CAR-T Cell Therapy
CAR-T cell therapy has taken the biotech industry by storm, creating hope that it could usher in a new era of cancer treatment. However, the success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is a highly competitive and is being targeted by numerous CAR-T cell therapy competitors.
Scientists, investors and developers invariably agree that the key to longer-term success in this sector depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products targeted against solid tumors will undoubtedly offer a larger market potential.
However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body’s B cells is not particularly problematic, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.
Driving Forces Impacting the CAR-T Cell Therapy Market
2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma produced Yescarta, a CAR-T therapy to designed for patients with lymphoma. Approvals for these products spread like wildfire, with the EU, Canada, Australia, Japan, and other nations following suit.
In July 2020, the U.S. FDA approved the third CAR-T cell therapy, approving Kite Pharma’s brexucabtagene autoleucel, sold as Tecartus. It is the first CAR-T therapeutic to treat relapsed or refractory mantle cell lymphoma (MCL).
By February 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb company. Breyanzi is approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. Shortly thereafter, Celgene Corporation, a Bristol Myers Squibb company, brought Abecma to market.
The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, from regulators, as well as the scientific and medical community at large.
Today, the CAR-T cell therapy industry is witnessing:
- Landmark approvals of CAR-T cell therapies by regulatory bodies worldwide
- Lucrative acquisitions within the CAR-T industry
- Large IPOs within the industry
- An increasingly competitive IP environment
- Unprecedented investment flowing into CAR-T cell research
CAR-T cell therapy has proven a promising new treatment approach. As its manufacture, administration, and safety profile improve, we are ushering in a new era of CAR-T cell therapeutics.
This global strategic report reveals:
- Market size determinations with segmentation and forecasts through 2028
- Approved CAR-T products by indication and region
- Clinical trial activity by type, region, phase, and sponsor
- CAR-T industry M&A transactions and IPOs
- Strategic partnerships and commercialization agreements
- Industry trends and future directions
- Competitors composing the global marketplace
This 235-page global strategic report will position you to:
- Capitalize on emerging trends
- Improve internal decision-making
- Reduce company risk
- Approach outside partners and investors
- Outcompete your competition
- Implement an informed and advantageous business strategy in 2021
In compiling this report, BioInformant’s analysts leveraged eight years of historical data on the CAR-T market. In addition to conducting extensive secondary research, our analysts interviewed dozens of highly regarded CAR-T industry leaders, including but not limited to those featured here.
With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.
TABLE OF CONTENTS: Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capital Hill.
The content within this report was compiled using a diverse range of sources, as described in this Research Methodology.
Remember, all BioInformant products come with a Greater Than 100% Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money, and you can keep the product.
Have questions? Email us at [email protected] to get a rapid reply. Checkout below to get immediate access to this report, with printing rights allowed.